|
Nitrosamine risk assessment for short-term therapies: lifetime assumptions versus less-than-lifetime (LTL) exposure
|
|
2
|
241
|
August 4, 2026
|
|
🦺 A new Home, the same community!
|
|
38
|
891
|
August 3, 2026
|
|
🇺🇸 FDA updates 'estimated duration' dates on Recommended Interim AI limits
|
|
1
|
281
|
August 3, 2026
|
|
🇺🇸 FDA Control of Nitrosamine Impurities in Human Drugs revision2
|
|
63
|
7259
|
October 3, 2025
|
|
N-Nitroso meglumine
|
|
34
|
3171
|
August 1, 2026
|
|
N-Nitroso Abacavir Impurity possibility in physical state as standard
|
|
5
|
182
|
August 1, 2026
|
|
QSAR Toolbox - Free software. Any experience?
|
|
22
|
2737
|
July 31, 2026
|
|
Integrating nitrosamine theoretical formation into Translational Pharmaceutics: Mitigating risks during accelerated formulation development in early phase clinical studies-Pub
|
|
0
|
148
|
July 28, 2026
|
|
Nitrosamine Workshop, Hyderabad, August 19 & 20
|
|
3
|
401
|
July 27, 2026
|
|
N-Nitroso Desmethyl Tramadol - Standard
|
|
3
|
294
|
July 27, 2026
|
|
Nitrosamines: Mass Spectrometry-Based Analytical Procedures Criterias
|
|
12
|
4767
|
July 25, 2026
|
|
Complex versus simple N-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigms -Pub
|
|
8
|
829
|
July 25, 2026
|
|
Which Molecule Is Involved in the Nitrosation Reaction of Pharmaceuticals: NO or NO 2 ? -Pub
|
|
3
|
306
|
July 24, 2026
|
|
CrN-coated punches and nitrosamine risk
|
|
0
|
106
|
July 23, 2026
|
|
AI limit for N-nitroso betahistine?
|
|
32
|
4861
|
July 23, 2026
|
|
Establishment of Limits in ppm (mg/kg) for Drug Products
|
|
2
|
288
|
July 22, 2026
|
|
MEGLUMINE (Methylglucamine)
|
|
31
|
4600
|
July 20, 2026
|
|
N-nitrosoproline
|
|
0
|
126
|
July 20, 2026
|
|
Determining Low PPB Levels of Nitrite in Polymeric Excipients
|
|
2
|
439
|
July 19, 2026
|
|
Less than daily administration
|
|
7
|
515
|
July 19, 2026
|
|
Nitrite Levels in Reverse Osmosis Water
|
|
7
|
479
|
July 17, 2026
|
|
Process-dependent N-nitroso-ketamine formation during ketamine active pharmaceutical ingredient manufacturing: part I impact of process design, solvent selection, and activated carbon-Pub
|
|
1
|
191
|
July 15, 2026
|
|
Trace-level LC–MS/MS quantification of two nitrosamine impurities formed from terazosin-related impurities in pharmaceutical products and greenness assessment-Pub
|
|
2
|
230
|
July 15, 2026
|
|
Requirements for NAs assessment in Russia
|
|
8
|
497
|
July 10, 2026
|
|
In Vitro Metabolism Study of NDSRIs
|
|
4
|
457
|
July 9, 2026
|
|
Research on Nitrosamines in Complex Preparations
|
|
4
|
412
|
July 8, 2026
|
|
Another Prazosin recall linked to N-nitroso-prazosin impurity C raises renewed concern for the finished product
|
|
10
|
947
|
July 7, 2026
|
|
Peptide Synthesis - Does anyone have experience with potential Nitrosamine impurities coming from solid phase synthesis?
|
|
2
|
329
|
July 6, 2026
|
|
Risk Evaluation of N-Nitrosamines in Drug-Linker Intermediates Used To Generate Antibody–Drug Conjugates -Pub
|
|
3
|
495
|
July 6, 2026
|
|
N-nitroso-Furosemide
|
|
4
|
806
|
July 6, 2026
|